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Abstract The importance of effective and timely
traceability in both the recall of substances of human
origin (blood, cells, tissues and organs) implicated in
infectious transmission, and in the prevention of
inappropriate use of substances of human origin is
now well recognised. However, traceability remains
poorly understood and inadequately controlled in
many cases. In particular there is: a lack of appreci-
ation of the complexity of the traceability pathway; a
fragmented approach to traceability; and, an assump-
tion that traceability data is static. The traceability
path for a single tissue donor may involve dozens or
even hundreds of different organizations, each respon-
sible foronesegmentofthe path.Whilstresponsibility
within each organization may be clearly deﬁned,
responsibility for maintaining the interfaces between
organizationsisoftenlessclear.Traceabilityisseldom
regarded in a holistic manner, the assumption being
made that if each segment of the pathway is correctly
maintained then the full path will be intact. End to end
traceability audits are not routinely performed, and the
only true test of the trail occurs when recall is
required—often with inadequate results.
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Introduction
Traceability in the ﬁeld of transplantation is generally
deﬁned as the ability to trace the path of a transplan-
tation product from the donor to the recipient,and vice
versa.
Incidents involving transmission of HCV through
transplantation, and the subsequent follow up inves-
tigations, have highlighted the importance of trace-
ability both in the prevention of infection and the
appropriate follow up of infected individuals. Incom-
plete or inaccurate traceability records can prevent
effective tracking of recipients and have been shown
to result in patients receiving tissue transplants from
infected donors that could have been avoided.
(Tugwell et al. 2005).
Policy makers are now recognising the importance
of traceability. In the most recent version of the
World Health Organizations Guiding Principles on
Organ and Tissue Transplantation (World Health
Organization 2010), guiding principle 10 states that:
‘‘The level of safety, efﬁcacy and quality of human
cells, tissues and organs for transplantation, as health
products of an exceptional nature, must be main-
tained and optimized on an ongoing basis. This
requires implementation of quality systems including
traceability and vigilance, with adverse events and
reactions reported, both nationally and for exported
human products’’.
Within European Directive 2004/EC/23 there is a
responsibility placed on Member States to ensure that
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distributed on their territory can be traced from the
donor to the recipient and vice versa. This traceability
shall also apply to all relevant data relating to
products and materials coming into contact with these
tissues and cells’’. (European Commission 2004).
In 2007 US agencies including Centers for Disease
Control and Prevention (CDC), Food and Drug
Administration (FDA), Health Resources and Ser-
vices Administration (HRSA) and Centers for Med-
icair and Medicaid Services (CMS) held a workshop
on Organ and Tissue Safety which recognised the
importance of timely tracking in order to identify and
expedite treatment for other recipients possibly
impacted by infected tissue (Fishman et al. 2009).
A report of the US Department of Health and Human
Services recognises that ‘‘A unique donor identiﬁer
that links all of the organs and tissues from a common
donor may facilitate the rapid identiﬁcation of all
allografts from that donor in the event of a public
safety concern’’. This same report also recognises the
importance of ensuring a comprehensive system of
tracking and vigilance for all biologics (blood, cells
tissues and organs) (US Department of Health and
Human Services 2009).
Despite such recognition, traceability remains
poorly understood and inadequately controlled in
many countries, and does not provide the necessary
responsiveness, reliability and longevity to ensure
patient safety.
There are three key reasons for this:
• there is a lack of appreciation of the complexity of
the information trail;
• traceability tends to be viewed in a fragmented
ratherthanholistic mannerwiththeassumptionthat
joining together the links at the time of information
retrieval will result in a full traceability chain;
• traceability data tends to be regarded as static
rather than dynamic with the assumption that if
the traceability path is intact today it will be so in
the future.
Complexity of the information trail
The concept of ‘a traceability path from donor to
recipient’ implies a one-to-one pathway, but this is
an oversimpliﬁcation of the real life situation. The
pathway between patient and donor is rarely one to
one. Most tissue donors donate a range of tissues
that will be divided and processed to produce
multiple grafts for use in many patients. Tissue
procurement may be performed by multiple teams
with the recovered tissue going to different tissue
banks.
A single tissue product may pass through several
different organizations on its journey from donor to
recipient. These may all be in the same country and
within the purview of a single regulatory authority, or
may span multiple countries and regulators.
Figure 1 illustrates a very simpliﬁed example of
organ and tissue recovery from a deceased donor, but
even with this simple model there are likely to be
between 12 and 20 different organizations involved in
the traceability trail. Where many hundreds of tissue
products are prepared, and where distributors are
involved as well as tissue banks, the number of
organization could easily run into the hundreds. Such
a situation may exist where highly processed bone is
produced in a large number of small packs for
dentistry applications.
Adding to the complexity is the fact that there is
generally no unique identiﬁcation of tissues from a
single donation event, hence the organ procurement
organization will use one identiﬁer, the eye bank a
second and the tissue bank a third. A lack of cross-
referencing between the procurement organization
identiﬁers means there is no formal traceability
across the different types of donation (in this case,
organs, eyes and musculoskeletal tissue).
The identiﬁers assigned will be unique within the
organization assigning them, but most likely not
once they leave the organization. As an example,
some US Tissue Banks may use the convention of
identifying a donor by the year of procurement
followed by a sequence number, thus 2010–001 is
the ﬁrst donation in 2010. This means that there
may be many different donors whose tissue is
identiﬁed by the reference 2010–001, one from each
tissue bank using this convention. The identiﬁer
alone is therefore not sufﬁcient to uniquely identify
the donor and it becomes necessary to identify the
supplying tissue bank throughout the information
trail. However, in many cases there will be no
uniform means of identifying the individual tissue
banks making such a system cumbersome, error-
prone and poorly suited to computerisation. In order
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tation transmission sentinel network (TTSN) has
been proposed and a pilot implementation has been
performed and evaluated (Joyce et al. 2010). The
pilot was successful and informative and further
evaluation is now under way.
Further complications can arise when a tissue is
transferred from one tissue bank to another, maybe
for additional specialised processing. In this case, the
number assigned by the ﬁrst bank is unlikely to be
compatible with the receiving bank’s system and thus
re-numbering of the tissue will occur.
By the time tissue grafts reach the operating room,
products from a single donation may be identiﬁed by
many different identiﬁers and supplied from many
different sources.
Because of the lack of unique identiﬁcation the
traceability pathway is very fragile. A single break in
the chain becomes a dead end with no alternative
means of picking up the trail.
Fragmented responsibility
The most common approach to traceability is to make
each organization that receives donor tissue respon-
sible for the traceability trail from the point of receipt
to the point of distribution. This scope will generally
include maintaining ‘pointers’ to the organization the
tissue was received from, and the organizations the
tissue was distributed to. Theoretically this ensures
that there is a complete traceability path regardless of
how many organizations the tissue passes through
between donor and recipient.
However, the ‘pointers’ are themselves vulnera-
ble, particularly over time as we will see when we
look at the dynamic nature of traceability data. In
addition, to work up the traceability trail from a
product implicated in an adverse reaction to the
donor, and then back down the trail to all other
tissue products from that donation will involve
many organizations and may take considerable time.
Fig. 1 Simpliﬁed example of organ and tissue recovery from a single donor
Cell Tissue Bank (2010) 11:329–333 331
123Where the traceability path moves across national
boundaries the reliability of the traceability trail in
practice may be doubtful.
There are some notable exceptions to the situation
described above. For example, in Italy the regulator
(competent authority) is informed of all donation
events and assigns a single donation identiﬁer that is
used to identify all organs and tissue procured from
the donor. A centralized system receives input from
all parties involved in handling the tissue from donor
to recipient and maintains a central database of the
entire information chain within the country (CEN
European Committee for Standardization Workshop
Agreement 2008). Such an approach addresses at a
national level many of the concerns regarding
fragmentation of the information trail, however there
still remain interfaces to be maintained at the point of
import to, and export from, the country.
Dynamic data
If, despite the challenges identiﬁed above, we are
conﬁdent that an intact traceability trail has been
formed, is it reasonable to assume this will always be
the case? European legislation requires that the
traceability trail be maintained for 30 years from the
point of graft usage. As some products have long shelf
lives, and organizations involved in the early part of
the chain may have no information on what the date of
usagewas,thiseffectivelymeanspermanentretention.
But is simply keeping the data equivalent to main-
taining the traceability trail?
Whilst the data trail within the organization is
likely to remain static, the vulnerability is in the
‘pointers’ to the supplying and receiving organiza-
tions. As an example (in which all the names used are
ﬁctitious) assume a tissue bank received bone product
with reference number 2002/002/0143 from Well-
brook Tissue Services in 2002. Wellbrook changed its
name in 2005 to New Hope Tissue Foundation, and in
2008 was purchased by Severnside Tissue Services.
The traceability trail now points to a non-existent
organization and the traceability trail is broken. It
may be possible to trace the new holders of the data,
but this can only be done by accessing information
that falls outside the traceability information set, and
indeed outside the control of the tissue bank
community and its regulators. The traceability trail
itself is compromised simply because the data stored
has been treated as static.
A further problem with the timescales involved is
technologies obsolescence and media degradation.
Electronic media is frequently used to provide long
term storage of traceability data, but the technologies
involved are in a constant state of change and today’s
‘‘state-of-the-art’’ storage system is likely to be
obsolete in less than 10 years. Even if systems are
maintained, media can degrade. Traceability may still
be possible but it is likely to take a long time. An
effective traceability strategy must include regular
data management reviews to assess data storage
needs and to implement timely data transfer to avoid
the obsolescence trap.
Effective traceability
With all of the above factors impacting upon the
traceability trail, the question has to be asked as to
how reliable traceability information really is. Where
audits are performed they are usually within one
organization and only verify the internal elements of
the trail. Holistic, end-to-end, audit is essential to
demonstrate the effectiveness of traceability, but is
rarely performed. Thus the only real test of effec-
tiveness tends to be in the live situation when
an adverse situation has occurred and tissue needs
to be withdrawn urgently. In such situations trace-
ability systems have often been found wanting with
long delays in tracing products and identifying
recipients, and some products and recipients never
being located.
Is there any way to improve this situation? By far
the most effective means of improving recall would
be the introduction of a globally unique donation
identiﬁcation number that is used on all tissue from a
single donor. Such an identiﬁer provides a rapid
alerting tool that can be used to help prevent the use
of compromised tissue. When deemed appropriate an
alert could be issued to the transplantation commu-
nity to suspend use of all, or a speciﬁc supplier subset
of, tissue bearing the speciﬁed unique identiﬁer.
Globally unique identiﬁcation also strengthens the
traceability trail as any single points of failure in the
traceability chain are far more likely to be overcome
if the reference number used in every organization is
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identify the assigning tissue bank responsible for
procurement, a ‘short-cut’ exists from the recipient
back to the donor allowing much more rapid tracing.
Even if a single identiﬁer for all organs and tissues
is not practical in the ﬁrst instance, use of globally
unique identiﬁers assigned to each group of tissue is
still a big step forward, as long as these initial
identiﬁers are carried on all tissue grafts prepared
from the procurement (e.g. in the scenario from
Fig. 1 distinct, but globally unique, identiﬁers are
issued by organ procurement, eye procurement and
tissue procurement teams). In this situation there
should ideally be a mechanism for cross-referencing
the identiﬁers assigned by each recovery team.
The second urgently required step is to introduce
end-to-end audit for traceability so that weaknesses
can be identiﬁed and rectiﬁed. Regulators and
professional bodies need to work together to deter-
mine the most appropriate means of achieving such
audits, and there needs to be clarity over where the
responsibility for traceability lies throughout the
entire pathway, and in particular over the manage-
ment of the interfaces between organizations. Audit
should also ensure that the long term viability of the
traceability trail is assured through regular review of
the data management strategy.
These two actions will not solve all the challenges
of effective traceability, but will go a long way to
improving the reliability of the traceability chain.
They will allow much more rapid recall thus short-
ening the ‘window period’ between risk identiﬁcation
and product withdrawal, hence increasing patient
safety.
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